Literature DB >> 10327215

Pharmacology of warfarin and clinical implications.

C Keller1, A C Matzdorff, B Kemkes-Matthes.   

Abstract

The history of oral anticoagulants started in the 1920s in North Dakota and Alberta when a new type of hemorrhagic disease struck cattle in these areas. The group of Karl Paul Link finally succeeded in isolating the causative agent, dicumarol. It was not before the 1940s, that dicumarol or its derivatives were introduced to medicine. Acenocoumarol, phenprocoumon, and warfarin are the most commonly used oral anticoagulants. There is no known difference in the pharmacodynamic activity of these agents on the vitamin K metabolism. They are completely absorbed from the gastrointestinal tract and are firmly bound to plasma albumin and metabolized in the liver. The different elimination half-lives of the coumarins have several implications for patient management. Absorption, protein binding, and anticoagulant activity of oral anticoagulants are affected in many different ways. Also the different pharmacological properties of coumarins require different strategies in the clinical management of patients.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10327215     DOI: 10.1055/s-2007-996418

Source DB:  PubMed          Journal:  Semin Thromb Hemost        ISSN: 0094-6176            Impact factor:   4.180


  3 in total

1.  Dichotomal effect of the coumadin derivative warfarin on inflammatory signal transduction.

Authors:  Arnon P Kater; Maikel P Peppelenbosch; Dees P M Brandjes; Mika Lumbantobing
Journal:  Clin Diagn Lab Immunol       Date:  2002-11

2.  The impact of acute diarrhea on the coagulation status of patients with vitamin K antagonists.

Authors:  Johannes Schweinfurth; Alexander Bauer; Frederic Bauer; Felix Sebastian Seibert; Benjamin Rohn; Maximilian Seidel; Sebastian Bertram; Ulrik Stervbo; Nina Babel; Timm Henning Westhoff
Journal:  Sci Rep       Date:  2021-06-03       Impact factor: 4.379

Review 3.  Practical guidance for using rivaroxaban in patients with atrial fibrillation: balancing benefit and risk.

Authors:  Sylvia Haas; Christoph Bode; Bo Norrving; Alexander Gg Turpie
Journal:  Vasc Health Risk Manag       Date:  2014-03-10
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.